|
GB8531071D0
(en)
*
|
1985-12-17 |
1986-01-29 |
Boots Co Plc |
Therapeutic compound
|
|
EP0647134A4
(de)
*
|
1992-06-23 |
1997-07-30 |
Sepracor Inc |
Verfahren und zusammensetzungen zur behandlung von depression und anderen erkrankungen unter verwendung von optisch-reinem sibutramin.
|
|
AU721924B2
(en)
*
|
1992-06-23 |
2000-07-20 |
Sepracor, Inc. |
Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
|
|
GB9301192D0
(en)
|
1993-06-09 |
1993-06-09 |
Trott Francis W |
Flower shaped mechanised table
|
|
US5459164A
(en)
*
|
1994-02-03 |
1995-10-17 |
Boots Pharmaceuticals, Inc. |
Medical treatment
|
|
DE19518988A1
(de)
*
|
1995-05-29 |
1996-12-05 |
Basf Ag |
Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
|
|
GB9619757D0
(en)
|
1996-09-21 |
1996-11-06 |
Knoll Ag |
Chemical process
|
|
GB9619961D0
(en)
|
1996-09-25 |
1996-11-13 |
Knoll Ag |
Medical treatment
|
|
GB9619962D0
(en)
*
|
1996-09-25 |
1996-11-13 |
Knoll Ag |
Medical treatment
|
|
GB9727131D0
(en)
|
1997-12-24 |
1998-02-25 |
Knoll Ag |
Therapeutic agents
|
|
US6339106B1
(en)
|
1999-08-11 |
2002-01-15 |
Sepracor, Inc. |
Methods and compositions for the treatment and prevention of sexual dysfunction
|
|
US6476078B2
(en)
*
|
1999-08-11 |
2002-11-05 |
Sepracor, Inc. |
Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
|
|
US6974838B2
(en)
|
1998-08-24 |
2005-12-13 |
Sepracor Inc. |
Methods of treating or preventing pain using sibutramine metabolites
|
|
US6331571B1
(en)
|
1998-08-24 |
2001-12-18 |
Sepracor, Inc. |
Methods of treating and preventing attention deficit disorders
|
|
US6046242A
(en)
*
|
1998-11-27 |
2000-04-04 |
Basf Aktiengesellschaft |
Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
|
|
US6323242B1
(en)
|
1998-12-02 |
2001-11-27 |
Peter Sterling Mueller |
Treatment of disorders secondary to organic impairments
|
|
US6696495B2
(en)
|
1998-12-02 |
2004-02-24 |
Snowden Pharmaceuticals, Llc |
Treatment of disorders secondary to organic impairments
|
|
BG65170B1
(bg)
*
|
1999-03-17 |
2007-05-31 |
Knoll Gmbh |
Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
|
|
WO2000056313A1
(en)
*
|
1999-03-19 |
2000-09-28 |
Knoll Gmbh |
Method of controlling weight gain associated with therapeutic drugs
|
|
AU3757200A
(en)
|
1999-03-19 |
2000-10-09 |
Knoll Gmbh |
Treatment of pulmonary hypertension
|
|
WO2000056310A1
(en)
|
1999-03-19 |
2000-09-28 |
Knoll Pharmaceutical Company |
Treatment of chronic fatigue syndrome
|
|
US6372798B1
(en)
|
1999-03-19 |
2002-04-16 |
Knoll Pharmaceutical Company |
Treatment of hyperactivity disorders
|
|
AU3894600A
(en)
|
1999-03-19 |
2000-10-09 |
Knoll Pharmaceutical Company |
Method of treating sexual dysfunction
|
|
US6803387B1
(en)
*
|
1999-03-19 |
2004-10-12 |
Abbott Gmbh & Co. Kg |
Treatment of neuropathic pain or fibromyalgia
|
|
AU3894500A
(en)
|
1999-03-19 |
2000-10-09 |
Knoll Pharmaceutical Company |
Prevention of cardiovascular disease
|
|
SK13342001A3
(sk)
*
|
1999-03-19 |
2002-04-04 |
Knoll Gmbh |
Použitie zlúčeniny a farmaceutická kompozícia ju obsahujúca
|
|
JP2002539252A
(ja)
*
|
1999-03-19 |
2002-11-19 |
クノール・ゲー・エム・ベー・ハー |
胆石の治療
|
|
US6552087B1
(en)
|
1999-03-19 |
2003-04-22 |
Abbott Gmbh & Co. Kg |
Therapeutic agent comprising (+)-sibutramine
|
|
WO2000056314A1
(en)
*
|
1999-03-19 |
2000-09-28 |
Knoll Gmbh |
Method of treating sleep apnoea
|
|
TR200102694T2
(tr)
*
|
1999-03-19 |
2002-04-22 |
Knoll Gmbh |
Hamilelik sonrası kilo kaybı.
|
|
US6365632B1
(en)
|
1999-03-19 |
2002-04-02 |
Knoll Pharmaceuticals Company |
Treatment of orthostatic hypotension
|
|
WO2000056311A1
(en)
*
|
1999-03-19 |
2000-09-28 |
Knoll Pharmaceutical Company |
Control of metabolism
|
|
CA2367666C
(en)
*
|
1999-03-19 |
2008-11-25 |
Carl M. Mendel |
Method of treating eating disorders
|
|
US6245782B1
(en)
|
1999-05-17 |
2001-06-12 |
Heartdrug Research L.L.C. |
Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
|
|
US6399826B1
(en)
|
1999-08-11 |
2002-06-04 |
Sepracor Inc. |
Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
|
|
GB9926251D0
(en)
*
|
1999-11-06 |
2000-01-12 |
Knoll Ag |
Pharmaceutical formulation
|
|
GB0004003D0
(en)
*
|
2000-02-22 |
2000-04-12 |
Knoll Ag |
Therapeutic agents
|
|
WO2002019998A2
(en)
*
|
2000-09-08 |
2002-03-14 |
Eli Lilly And Company |
A method of treating weight gain associated with atypical antipsychotic use
|
|
FR2814678B1
(fr)
†
|
2000-10-04 |
2002-12-20 |
Aventis Pharma Sa |
Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
|
|
US20020091114A1
(en)
|
2000-10-04 |
2002-07-11 |
Odile Piot-Grosjean |
Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
|
|
US6610887B2
(en)
|
2001-04-13 |
2003-08-26 |
Sepracor Inc. |
Methods of preparing didesmethylsibutramine and other sibutramine derivatives
|
|
US20030139386A1
(en)
*
|
2001-12-21 |
2003-07-24 |
Sophie Cote |
Pharmaceutical compositions based on azetidine derivatives
|
|
NZ534757A
(en)
*
|
2002-03-12 |
2006-07-28 |
Merck & Co Inc |
Substituted amides
|
|
US7105526B2
(en)
|
2002-06-28 |
2006-09-12 |
Banyu Pharmaceuticals Co., Ltd. |
Benzimidazole derivatives
|
|
US20040122033A1
(en)
*
|
2002-12-10 |
2004-06-24 |
Nargund Ravi P. |
Combination therapy for the treatment of obesity
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
US20050131074A1
(en)
*
|
2003-08-04 |
2005-06-16 |
Beckman Kristen M. |
Methods for treating metabolic syndrome
|
|
CN1902177A
(zh)
|
2003-09-22 |
2007-01-24 |
万有制药株式会社 |
新哌啶衍生物
|
|
EP1734963A4
(de)
|
2004-04-02 |
2008-06-18 |
Merck & Co Inc |
Verfahren zur behandlung von menschen mit metabolischen und anthropometrischen störungen
|
|
EP1846359A4
(de)
|
2005-01-06 |
2010-03-31 |
Cj Cheiljedang Corp |
Salze von sibutramin mit anorganischen säuren
|
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
|
EP1892241B1
(de)
|
2005-05-30 |
2016-03-30 |
Msd K.K. |
Neues piperidinderivat
|
|
US20100216758A1
(en)
|
2005-08-10 |
2010-08-26 |
Makoto Ando |
Pyridone Compounds
|
|
DE602006017712D1
(de)
|
2005-08-24 |
2010-12-02 |
Banyu Pharma Co Ltd |
Phenylpyridonderivat
|
|
CA2621470A1
(en)
|
2005-09-07 |
2007-03-15 |
Banyu Pharmaceutical Co., Ltd. |
Bicyclic aromatic substituted pyridone derivative
|
|
EP1938811A4
(de)
*
|
2005-09-22 |
2008-12-17 |
Eisai R&D Man Co Ltd |
Medizinische zusammensetzung zur behandlung von bulimie und mit bulimie einhergehenden depressionen
|
|
CA2624030A1
(en)
|
2005-09-29 |
2007-04-12 |
Tianying Jian |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
|
US8911751B2
(en)
*
|
2005-10-11 |
2014-12-16 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Compositions for nasal delivery
|
|
US20080255084A1
(en)
|
2005-10-21 |
2008-10-16 |
Randy Lee Webb |
Combination of Organic Compounds
|
|
WO2007049798A1
(ja)
|
2005-10-27 |
2007-05-03 |
Banyu Pharmaceutical Co., Ltd. |
新規ベンゾオキサチイン誘導体
|
|
RU2428423C2
(ru)
|
2005-11-10 |
2011-09-10 |
Баниу Фармасьютикал Ко., Лтд. |
Азазамещенные спиропроизводные
|
|
US8748419B2
(en)
|
2006-06-16 |
2014-06-10 |
Theracos, Inc. |
Treating obesity with muscarinic receptor M1 antagonists
|
|
RU2455981C2
(ru)
*
|
2006-06-16 |
2012-07-20 |
Теракос, Инк. |
Лечение ожирения антагонистами мускаринового рецептора м1
|
|
CN101511364B
(zh)
|
2006-09-07 |
2012-08-15 |
奈科明有限责任公司 |
用于糖尿病的治疗组合
|
|
MX2009002781A
(es)
*
|
2006-09-15 |
2009-03-30 |
Reviva Pharmaceuticals Inc |
Sintesis, metodos de uso y composiciones de cicloalquilmetilaminas .
|
|
WO2008039327A2
(en)
|
2006-09-22 |
2008-04-03 |
Merck & Co., Inc. |
Method of treatment using fatty acid synthesis inhibitors
|
|
US20090247560A1
(en)
|
2006-09-28 |
2009-10-01 |
Banyu Pharmaceutical Co., Ltd. |
Diaryl ketimine derivative
|
|
KR20090127904A
(ko)
*
|
2007-04-09 |
2009-12-14 |
싸이도우스 엘엘씨. |
스타틴과 항비만제의 복합물
|
|
US20080249156A1
(en)
*
|
2007-04-09 |
2008-10-09 |
Palepu Nageswara R |
Combinations of statins and anti-obesity agent and glitazones
|
|
ES2393885T7
(es)
|
2007-06-04 |
2014-01-30 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
|
CA2690004C
(en)
|
2007-06-04 |
2018-01-23 |
Ben-Gurion University Of The Negev Research And Development Authority |
Tri-aryl compounds and compositions comprising the same
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
EP2264026A4
(de)
|
2008-03-06 |
2012-03-28 |
Msd Kk |
Alkylaminopyridinderivate
|
|
US20110015198A1
(en)
|
2008-03-28 |
2011-01-20 |
Banyu Pharmaceutical Co., Inc. |
Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
|
|
ES2627848T3
(es)
|
2008-06-04 |
2017-07-31 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
|
JPWO2009154132A1
(ja)
|
2008-06-19 |
2011-12-01 |
Ｍｓｄ株式会社 |
スピロジアミン−ジアリールケトオキシム誘導体
|
|
AU2009270833B2
(en)
|
2008-07-16 |
2015-02-19 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
|
CA2731358A1
(en)
|
2008-07-30 |
2010-02-04 |
Banyu Pharmaceutical Co., Ltd. |
5/5-or 5/6-membered condensed ring cycloalkylamine derivative
|
|
US8410284B2
(en)
|
2008-10-22 |
2013-04-02 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
|
EP2362731B1
(de)
|
2008-10-31 |
2016-04-06 |
Merck Sharp & Dohme Corp. |
Neue nützlich anti-diabetische mittel mit zyklische benzimidazol-derivate
|
|
WO2010065889A2
(en)
*
|
2008-12-06 |
2010-06-10 |
Auspex Pharmaceutical |
Cyclobutanemethanamine inhibitors of monomine reuptake
|
|
EP2379547A1
(de)
|
2008-12-16 |
2011-10-26 |
Schering Corporation |
Pyridopyrimidinderivate und verfahren zu deren anwendung
|
|
EP2379562A1
(de)
|
2008-12-16 |
2011-10-26 |
Schering Corporation |
Bicyclische pyranonderivate als agonisten am nicotinsäurerezeptor
|
|
AU2011218830B2
(en)
|
2010-02-25 |
2014-07-24 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
WO2012003501A2
(en)
|
2010-07-02 |
2012-01-05 |
Reviva Pharmaceuticals, Inc. |
Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
ES2652662T3
(es)
|
2011-02-25 |
2018-02-05 |
Merck Sharp & Dohme Corp. |
Novedosos derivados de azabencimidazol cíclicos útiles como agentes antidiabéticos
|
|
BR112015002080A2
(pt)
|
2012-08-02 |
2017-07-04 |
Merck Sharp & Dohme |
composto, composição farmacêutica, uso de um composto, e, método de tratamento ou de prevenção de um transtorno, de uma condição ou de uma doença
|
|
CA2898482A1
(en)
|
2013-02-22 |
2014-08-28 |
Linda L. Brockunier |
Antidiabetic bicyclic compounds
|
|
EP2970119B1
(de)
|
2013-03-14 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Neuartige indolderivate als antidiabetika
|
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
|
CA2905435A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
|
WO2014197720A2
(en)
|
2013-06-05 |
2014-12-11 |
Synergy Pharmaceuticals, Inc. |
Ultra-pure agonists of guanylate cyclase c, method of making and using same
|
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
JP6657101B2
(ja)
|
2013-11-05 |
2020-03-04 |
ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ |
糖尿病及びそれから生じる疾患合併症の治療のための化合物
|
|
CN107207483B
(zh)
|
2014-08-29 |
2020-10-30 |
Tes制药有限责任公司 |
α-氨基-β-羧基粘康酸半醛脱羧酶抑制剂
|
|
AU2017342083A1
(en)
|
2016-10-14 |
2019-04-11 |
Tes Pharma S.R.L. |
Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
|
|
WO2018106518A1
(en)
|
2016-12-06 |
2018-06-14 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
|
US10968232B2
(en)
|
2016-12-20 |
2021-04-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
|
EP3883930A1
(de)
|
2018-11-20 |
2021-09-29 |
Tes Pharma S.r.l. |
Inhibitoren der alpha-amino-beta-carboxymuconsäure-semialdehyddecarboxylase
|